CommunitiesBreast CancerWhat is the success rate of Enhertu for liver metastasis?

What is the success rate of Enhertu for liver metastasis?

GJ

Community Member

4 months ago

Hello people. Haven't been here in a while. Got a lot on my plate. Come to find out my second time trying a chemo and hormonal treatment and didn't work. Come to find out I have three spots on my liver now and now I have to get a port to take my intravenous chemo which is the Enhertu. Anybody know the success rate on that? Thanks for listening. Talk to you later on my next journey with a new chemo plan.

2 comments
Comment
accepted answer

Accepted Answer

Enhertu has shown promising results in clinical trials for metastatic breast cancer, though response rates can vary based on individual factors like cancer subtype and previous treatments. Many community members have shared their experiences with this treatment, and connecting with others who have been on similar treatment paths might provide helpful insights alongside discussions with your medical team about what to expect.

3+ patients found this helpful

•O

Community Member

4 months ago

Hi Gemmz. This is definitely not the news we want to hear but I’m so glad you are here. Did you update your diagnosis in the app yet? Once you do you will be given access to communities with other patients who are dealing with treating their metastatic breast cancer. Connecting there will likely be the most helpful to you. Please let me know if we can help you with this update. 💛 Suzanne (Community Moderator)

0
CA

Community Member

2 months ago

Enhertu has shown promising results in clinical trials for metastatic breast cancer, though response rates can vary based on individual factors like cancer subtype and previous treatments. Many community members have shared their experiences with this treatment, and connecting with others who have been on similar treatment paths might provide helpful insights alongside discussions with your medical team about what to expect.

Outcomes4Me

© 2025 Outcomes4Me Inc. All rights reserved.